Search results
General Partner Inc. Buys 1,792 Shares of AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 15 hours agoGeneral Partner Inc. boosted its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 716.8% in the first quarter, according to its most recent disclosure with the Securities ...
AbbVie Inc. (NYSE:ABBV) Shares Bought by First Financial Bank Trust Division
ETF DAILY NEWS· 15 hours agoFirst Financial Bank Trust Division boosted its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 967.2% during the 1st quarter, according to the company in its ...
Why AbbVie (ABBV) is a Great Dividend Stock Right Now
Zacks via Yahoo Finance· 13 hours agoDividends are one of the best benefits to being a shareholder, but finding a great dividend stock is...
AbbVie Inc. (NYSE:ABBV) Shares Sold by Michael S. Ryan Inc.
ETF DAILY NEWS· 20 hours agoMichael S. Ryan Inc. lowered its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 2.6% in the first quarter, according to its most recent disclosure with the SEC. The ...
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
Zacks via Yahoo Finance· 16 hours agoAbbVie ABBV announced that the FDA has granted approval to its blockbuster drug, Skyrizi to treat...
AbbVie (NYSE:ABBV) Stock Price Up 1.5% on Analyst Upgrade
ETF DAILY NEWS· 1 day agoAbbVie Inc. (NYSE:ABBV – Get Free Report) shares rose 1.5% during trading on Tuesday after Piper Sandler raised their price target on the stock from $185.00 to $190.00. Piper ...
AbbVie says FDA approves Skyrizi for ulcerative colitis
Market Watch· 1 day agoDrug maker AbbVie Inc. on Tuesday said the Food and Drug Administration had approved its drug...
AbbVie (ABBV) Exceeds Market Returns: Some Facts to Consider
Zacks via Yahoo Finance· 1 day agoThe latest trading session saw AbbVie (ABBV) ending at $171.36, denoting a +0.99% adjustment from...
Canandaigua National Bank & Trust Co. Trims Holdings in AbbVie Inc. (NYSE:ABBV)
ETF DAILY NEWS· 17 hours agoCanandaigua National Bank & Trust Co. reduced its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 3.1% in the 1st quarter, according to the company in its most ...
AbbVie’s SKYRIZI gains US FDA approval for ulcerative colitis
Pharmaceutical Technology via Yahoo Finance· 20 hours agoAbbVie has announced receipt of US Food and Drug Administration (FDA) approval for SKYRIZI...